8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): August 18, 2014

Medytox Solutions, Inc.
(Exact Name of Registrant as Specified in Its Charter)

Nevada
(State or Other Jurisdiction of Incorporation)

000-54346	54-2156042
(Commission File Number)	(I.R.S. Employer Identification No.)

400 S. Australian Avenue, Suite 800, West Palm Beach, Florida	33401
(Address of Principal Executive Offices)	(Zip Code)

(561) 855-1626

(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01.     Other Events.

On August 18, 2014, the Registrant issued the press release attached hereto as Exhibit 99.1, regarding its results for the three and six months ended June 30, 2014.

Item 9.01.     Financial Statements and Exhibits.

Exhibit
No.	Item
99.1	Press Release dated August 18, 2014

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MEDYTOX SOLUTIONS, INC.
Date: August 18, 2014	By:	/s/ William G. Forhan
		William G. Forhan, CEO and Chairman (principal executive officer)

3

EX-99.1

Exhibit 99.1

Medytox Solutions, Inc. Announces Results for the Three and Six Months
Ended June 30, 2014

Medytox Solutions, Inc. (OTCQB: MMMS) (August 18, 2014) announced today its financial results for the three-month period ended June 30, 2014 (the “2014 Quarter”), and the six-month period ended June 30, 2014 (the "2014 Period"). For the 2014 Quarter, the Company reported revenues of approximately $20.1 million, which represented an increase of approximately $12.2 million, or 142%, from the approximately $8.6 million in revenues reported for the same period of the prior year (the “2013 Quarter”). For the 2014 Period, the Company reported revenues of approximately $41.8 million, which represented an increase of approximately $25.2 million, or 152, from the approximately $16.6 million in revenues reported for the same period of the prior year (the “2013 Period”). For the 2014 Quarter, the Company reported income from operations of approximately $5.8 million, compared to income from operations of approximately $0.9 million for the 2013 Quarter. For the 2014 Period, the Company reported income from operations of approximately $12.7 million, as compared to income from operations of approximately $2.2 million for the 2013 Period.

“Our results for the three and nine months ended June 30, 2014 are due to our continued commitment to all our customers," stated William Forhan, the Company’s Chief Executive Officer. "We also appreciate all our employees, who work hard to deliver excellent customer service.”

The Company is a holding company that owns and operates businesses in the medical services sector. Our principal line of business is clinical laboratory blood and urine testing services, with a particular emphasis in the provision of urine drug toxicology and comprehensive pain medication monitoring programs to physicians, clinics and rehabilitation facilities in the United States.

1

MEDYTOX SOLUTIONS, INC.

Condensed Consolidated Statements of Operations

(Unaudited)

	For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2014			2013			2014			2013
Revenues	$	20,784,426		$	8,602,577		$	41,846,998		$	16,626,336
Total operating expenses		14,986,134			7,675,800			29,184,625			14,442,103
Income from operations		5,798,292			926,777			12,662,370			2,184,233
Total other income (expense)		(100,813	)		(122,700	)		(63,258	)		(332,843	)
Income before income taxes		5,697,479			804,077			12,599,112			1,851,390
Provision for income taxes		2,198,000			120,800			4,796,100			514,900
Net income attributable to Medytox Solutions		3,499,479			683,277			7,803,012			1,336,490
Preferred stock dividends		1,510,542			244,365			2,424,105			483,106
Net income attributable to Medytox Solutions common shareholders	$	1,988,937		$	438,912		$	5,378,907		$	853,384
Net income per common share - Basic	$	0.07		$	0.01		$	0.18		$	0.03
Diluted	$	0.06		$	0.02		$	0.18		$	0.03
Weighted average number of common shares outstanding during the period - Basic		30,247,265			29,572,076			30,145,723			29,567,814
Diluted		30,669,487			29,955,309			30,482,862			29,931,047

2

“Forward-looking” Statements

This press release may contain “forward-looking” statements, as defined in the Private Securities Litigation Reform Act of 1995, as amended. Any such statements are made pursuant to the safe-harbor provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, and they involve a number of risks and uncertainties that could cause actual results to differ materially from those that may be anticipated by or from the forward-looking statements. Important factors that could cause such a difference are set forth in the Company’s filings with the Securities and Exchange Commission and include, but are not limited to the ability to consummate acquisitions and the ability to integrate such acquisitions.

Contact:	Sebastien Sainsbury ssainsbury@medytoxsolutionsinc.com
	400 South Australian Avenue, 8th Floor
	West Palm Beach, Florida 33401

3